MMCAP International Inc. SPC Acquires 8.0% Stake in Akari Therapeutics, Plc.

On June 8, 2026, MMCAP International Inc. SPC and MM Asset Management Inc. filed a Schedule 13G reporting a new 8.0% stake in Akari Therapeutics, Plc. (AKTX). The reporting persons disclosed beneficial ownership of 8,000,000,000 ordinary shares, which are represented by 100,000 American Depository Shares (ADS). Each ADS is convertible into 80,000 ordinary shares of the issuer. The event triggering this filing occurred on June 2, 2026. The ownership percentage was calculated based on approximately 91.57 billion ordinary shares outstanding as of March 31, 2026. MMCAP International Inc. SPC, based in the Cayman Islands, and Ontario-based MM Asset Management Inc. share voting and dispositive power over the reported shares. The filing includes a standard certification indicating that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. This initial filing represents a significant new position for the investment management group in the clinical-stage biopharmaceutical company.